Adaptimmune Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Accrued expenses and other current liabilities

Accrued expenses and other current liabilities

12 Months Ended

Dec. 31, 2019

Accrued expenses and other current liabilities

Accrued expenses and other current liabilities

Note 9 — Accrued expenses and other current liabilities

Accrued expenses and other current liabilities consisted of the following (in thousands):


	December 31,		December 31,
	2019		2018
Accrued clinical and development expenditure	$	8,782	$	9,637
Accrued employee expenses		6,863		7,553
Other accrued expenditure		2,662		2,422
Accrued purchase commitments		5,000		—
Other		56		742
	$	23,363	$	20,354

In 2016, the Company entered into a supply agreement with ThermoFisher for the supply of the Dynabeads® CD3/CD28 technology. The supply agreement runs until December 31, 2025. Under the supply agreement, the Company is required to purchase its requirements for CD3/CD28 magnetic bead product exclusively from ThermoFisher for a period of 5 years. There are minimum purchasing obligations of $5.0 million, $2.5 million of which is payable in 2020 and $2.5 million of which is payable in 2021. Management regularly updates the assessment of the utility of the Dynabeads, and in the year ended December 31, 2019, considered that there is sufficient uncertainty surrounding the utility of the Dynabeads, which is dependent upon current study trajectories, the Company’s clinical pipeline, manufacturing methods and undetermined future projects, to result in the $5.0 million purchase commitment being recognized in Research and development expense in the year ended December 31, 2019.